Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks

Hans Christop Diener, G. Bussone, H. De Liano, A. Eikermann, R. Englert, T. Floeter, V. Gallai, H. Göbel, E. Hartung, M. D. Jimenez, R. Lange, G. C. Manzoni, G. Mueller-Schwefe, G. Nappi, L. Pinessi, J. Prat, F. M. Puca, F. Titus, M. Voelker

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Acetylsalicylic acid (ASA) in combination with metoclopramide has been frequently used in clinical trials in the acute treatment of migraine attacks. Recently the efficacy of a new high buffered formulation of 1000 mg effervescent ASA without metoclopramide compared to placebo has been shown. To further confirm the efficacy of this new formulation in comparison with a triptan and a nonsteroidal anti-inflammatory drug (ibuprofen) a three-fold crossover, double-blind, randomized trial with 312 patients was conducted in Germany, Italy and Spain. Effervescent ASA (1000 mg) was compared to encapsulated sumatriptan (50 mg), ibuprofen (400 mg) and placebo. The percentage of patients with reduction in headache severity from moderate or severe to mild or no pain (primary endpoint) was 52.5% for ASA, 60.2% for ibuprofen, 55.8% for sumatriptan and 30.6% for placebo. All active treatments were superior to placebo (P <0.0001), whereas active treatments were not statistically different. The number of patients who were pain-free at 2 h was 27.1%, 33.2%, 37.1% and 12.6% for those treated with ASA, ibuprofen, sumatriptan or placebo, respectively. The difference between ASA and sumatriptan was statistically significant (P = 0.025). With respect to other secondary efficacy criteria and accompanying symptoms no statistically significant differences between ASA and ibuprofen or sumatriptan were found. Drug-related adverse events were reported in 4.1%, 5.7%, 6.6% and 4.5% of patients treated with ASA, ibuprofen sumatriptan or placebo. This study showed that 1000 mg effervescent ASA is as effective as 50 mg sumatriptan and 400 mg ibuprofen in the treatment of migraine attacks regarding headache relief from moderate/severe to mild/no pain at 2 h. Regarding pain-free at 2 h sumatriptan was most effective.

Original languageEnglish
Pages (from-to)947-954
Number of pages8
JournalCephalalgia
Volume24
Issue number11
DOIs
Publication statusPublished - Nov 2004

Fingerprint

Sumatriptan
Ibuprofen
Migraine Disorders
Aspirin
Placebos
Metoclopramide
Therapeutics
Headache
Tryptamines
Drug-Related Side Effects and Adverse Reactions
Spain
Italy
Germany
Anti-Inflammatory Agents
Clinical Trials

Keywords

  • Acetylsalicylic acid
  • Ibuprofen
  • Migraine
  • Placebo
  • Randomized controlled crossover trial
  • Sumatriptan

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Diener, H. C., Bussone, G., De Liano, H., Eikermann, A., Englert, R., Floeter, T., ... Voelker, M. (2004). Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia, 24(11), 947-954. https://doi.org/10.1111/j.1468-2982.2004.00783.x

Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. / Diener, Hans Christop; Bussone, G.; De Liano, H.; Eikermann, A.; Englert, R.; Floeter, T.; Gallai, V.; Göbel, H.; Hartung, E.; Jimenez, M. D.; Lange, R.; Manzoni, G. C.; Mueller-Schwefe, G.; Nappi, G.; Pinessi, L.; Prat, J.; Puca, F. M.; Titus, F.; Voelker, M.

In: Cephalalgia, Vol. 24, No. 11, 11.2004, p. 947-954.

Research output: Contribution to journalArticle

Diener, HC, Bussone, G, De Liano, H, Eikermann, A, Englert, R, Floeter, T, Gallai, V, Göbel, H, Hartung, E, Jimenez, MD, Lange, R, Manzoni, GC, Mueller-Schwefe, G, Nappi, G, Pinessi, L, Prat, J, Puca, FM, Titus, F & Voelker, M 2004, 'Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks', Cephalalgia, vol. 24, no. 11, pp. 947-954. https://doi.org/10.1111/j.1468-2982.2004.00783.x
Diener, Hans Christop ; Bussone, G. ; De Liano, H. ; Eikermann, A. ; Englert, R. ; Floeter, T. ; Gallai, V. ; Göbel, H. ; Hartung, E. ; Jimenez, M. D. ; Lange, R. ; Manzoni, G. C. ; Mueller-Schwefe, G. ; Nappi, G. ; Pinessi, L. ; Prat, J. ; Puca, F. M. ; Titus, F. ; Voelker, M. / Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. In: Cephalalgia. 2004 ; Vol. 24, No. 11. pp. 947-954.
@article{899d3d1bd1ab4d048bb06925060ac665,
title = "Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks",
abstract = "Acetylsalicylic acid (ASA) in combination with metoclopramide has been frequently used in clinical trials in the acute treatment of migraine attacks. Recently the efficacy of a new high buffered formulation of 1000 mg effervescent ASA without metoclopramide compared to placebo has been shown. To further confirm the efficacy of this new formulation in comparison with a triptan and a nonsteroidal anti-inflammatory drug (ibuprofen) a three-fold crossover, double-blind, randomized trial with 312 patients was conducted in Germany, Italy and Spain. Effervescent ASA (1000 mg) was compared to encapsulated sumatriptan (50 mg), ibuprofen (400 mg) and placebo. The percentage of patients with reduction in headache severity from moderate or severe to mild or no pain (primary endpoint) was 52.5{\%} for ASA, 60.2{\%} for ibuprofen, 55.8{\%} for sumatriptan and 30.6{\%} for placebo. All active treatments were superior to placebo (P <0.0001), whereas active treatments were not statistically different. The number of patients who were pain-free at 2 h was 27.1{\%}, 33.2{\%}, 37.1{\%} and 12.6{\%} for those treated with ASA, ibuprofen, sumatriptan or placebo, respectively. The difference between ASA and sumatriptan was statistically significant (P = 0.025). With respect to other secondary efficacy criteria and accompanying symptoms no statistically significant differences between ASA and ibuprofen or sumatriptan were found. Drug-related adverse events were reported in 4.1{\%}, 5.7{\%}, 6.6{\%} and 4.5{\%} of patients treated with ASA, ibuprofen sumatriptan or placebo. This study showed that 1000 mg effervescent ASA is as effective as 50 mg sumatriptan and 400 mg ibuprofen in the treatment of migraine attacks regarding headache relief from moderate/severe to mild/no pain at 2 h. Regarding pain-free at 2 h sumatriptan was most effective.",
keywords = "Acetylsalicylic acid, Ibuprofen, Migraine, Placebo, Randomized controlled crossover trial, Sumatriptan",
author = "Diener, {Hans Christop} and G. Bussone and {De Liano}, H. and A. Eikermann and R. Englert and T. Floeter and V. Gallai and H. G{\"o}bel and E. Hartung and Jimenez, {M. D.} and R. Lange and Manzoni, {G. C.} and G. Mueller-Schwefe and G. Nappi and L. Pinessi and J. Prat and Puca, {F. M.} and F. Titus and M. Voelker",
year = "2004",
month = "11",
doi = "10.1111/j.1468-2982.2004.00783.x",
language = "English",
volume = "24",
pages = "947--954",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "11",

}

TY - JOUR

T1 - Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks

AU - Diener, Hans Christop

AU - Bussone, G.

AU - De Liano, H.

AU - Eikermann, A.

AU - Englert, R.

AU - Floeter, T.

AU - Gallai, V.

AU - Göbel, H.

AU - Hartung, E.

AU - Jimenez, M. D.

AU - Lange, R.

AU - Manzoni, G. C.

AU - Mueller-Schwefe, G.

AU - Nappi, G.

AU - Pinessi, L.

AU - Prat, J.

AU - Puca, F. M.

AU - Titus, F.

AU - Voelker, M.

PY - 2004/11

Y1 - 2004/11

N2 - Acetylsalicylic acid (ASA) in combination with metoclopramide has been frequently used in clinical trials in the acute treatment of migraine attacks. Recently the efficacy of a new high buffered formulation of 1000 mg effervescent ASA without metoclopramide compared to placebo has been shown. To further confirm the efficacy of this new formulation in comparison with a triptan and a nonsteroidal anti-inflammatory drug (ibuprofen) a three-fold crossover, double-blind, randomized trial with 312 patients was conducted in Germany, Italy and Spain. Effervescent ASA (1000 mg) was compared to encapsulated sumatriptan (50 mg), ibuprofen (400 mg) and placebo. The percentage of patients with reduction in headache severity from moderate or severe to mild or no pain (primary endpoint) was 52.5% for ASA, 60.2% for ibuprofen, 55.8% for sumatriptan and 30.6% for placebo. All active treatments were superior to placebo (P <0.0001), whereas active treatments were not statistically different. The number of patients who were pain-free at 2 h was 27.1%, 33.2%, 37.1% and 12.6% for those treated with ASA, ibuprofen, sumatriptan or placebo, respectively. The difference between ASA and sumatriptan was statistically significant (P = 0.025). With respect to other secondary efficacy criteria and accompanying symptoms no statistically significant differences between ASA and ibuprofen or sumatriptan were found. Drug-related adverse events were reported in 4.1%, 5.7%, 6.6% and 4.5% of patients treated with ASA, ibuprofen sumatriptan or placebo. This study showed that 1000 mg effervescent ASA is as effective as 50 mg sumatriptan and 400 mg ibuprofen in the treatment of migraine attacks regarding headache relief from moderate/severe to mild/no pain at 2 h. Regarding pain-free at 2 h sumatriptan was most effective.

AB - Acetylsalicylic acid (ASA) in combination with metoclopramide has been frequently used in clinical trials in the acute treatment of migraine attacks. Recently the efficacy of a new high buffered formulation of 1000 mg effervescent ASA without metoclopramide compared to placebo has been shown. To further confirm the efficacy of this new formulation in comparison with a triptan and a nonsteroidal anti-inflammatory drug (ibuprofen) a three-fold crossover, double-blind, randomized trial with 312 patients was conducted in Germany, Italy and Spain. Effervescent ASA (1000 mg) was compared to encapsulated sumatriptan (50 mg), ibuprofen (400 mg) and placebo. The percentage of patients with reduction in headache severity from moderate or severe to mild or no pain (primary endpoint) was 52.5% for ASA, 60.2% for ibuprofen, 55.8% for sumatriptan and 30.6% for placebo. All active treatments were superior to placebo (P <0.0001), whereas active treatments were not statistically different. The number of patients who were pain-free at 2 h was 27.1%, 33.2%, 37.1% and 12.6% for those treated with ASA, ibuprofen, sumatriptan or placebo, respectively. The difference between ASA and sumatriptan was statistically significant (P = 0.025). With respect to other secondary efficacy criteria and accompanying symptoms no statistically significant differences between ASA and ibuprofen or sumatriptan were found. Drug-related adverse events were reported in 4.1%, 5.7%, 6.6% and 4.5% of patients treated with ASA, ibuprofen sumatriptan or placebo. This study showed that 1000 mg effervescent ASA is as effective as 50 mg sumatriptan and 400 mg ibuprofen in the treatment of migraine attacks regarding headache relief from moderate/severe to mild/no pain at 2 h. Regarding pain-free at 2 h sumatriptan was most effective.

KW - Acetylsalicylic acid

KW - Ibuprofen

KW - Migraine

KW - Placebo

KW - Randomized controlled crossover trial

KW - Sumatriptan

UR - http://www.scopus.com/inward/record.url?scp=8144227572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8144227572&partnerID=8YFLogxK

U2 - 10.1111/j.1468-2982.2004.00783.x

DO - 10.1111/j.1468-2982.2004.00783.x

M3 - Article

C2 - 15482357

AN - SCOPUS:8144227572

VL - 24

SP - 947

EP - 954

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 11

ER -